Magellan intends to focus on LeadCare and Dynex businesses.
The company plans to unveil Dynex Agility ELISA processing system.
Magellan claims its LeadCare II three-minute blood-lead test improves screening rates compared to traditional lab-based testing and send-out methods.
Magellan president and CEO Hiroshi Uchida said TREK’s automated blood culture, microbial identification, and microbial susceptibility testing platforms complement Thermo Fisher’s portfolio of microbiology technologies.
"We will now focus on realizing our ambitious plans for expanding the reach and growth of our remaining businesses," Uchida said.
